KeyBanc analyst Scott Schoenhaus maintains $Recursion Pharmaceuticals (RXRX.US)$ with a buy rating, and adjusts the target price from $12 to $10.
According to TipRanks data, the analyst has a success rate of 37.1% and a total average return of -2.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Recursion Pharmaceuticals (RXRX.US)$'s main analysts recently are as follows:
While political and rate uncertainties persist as concerns, the overall condition of the Biopharma sector is seen as greatly enhanced from its lows in 2022. Among the stocks evaluated, preference is given to those in later-stage clinical trials or early launch phases; however, there's a growing investor interest in Phase 1 clinical programs that present near-term catalysts and data which reduce risks.
Healthcare technology stocks were generally under pressure for most of last year but witnessed a recovery in the last two months following the election. Coupled with cuts to consensus estimates since mid-last year, there appears to be attractive buying opportunities in the sector for 2025. Analysts believe that companies with robust balance sheets and consistent free cash flow profiles will face less risk of multiple contraction, despite potentially modest growth trends. On the contrary, the greatest risk is perceived for companies that have strained balance sheets and limited profitability prospects in both the near and longer term.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.